CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt T, Hufnagl C, Magnes T, Weiss L, Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Tränkenschuh W, et al. BMC Cancer. 2015 Oct 16; 15:725. Epub 2015 Oct 16.